WWB WINDWARD BIO GROUP AG 424B4 final IPO prospectus section summaries
An AI model summarized each section of the prospectus on its own; the summary was written from these. They are longer and less edited than the summary, and the filing on SEC is the authority.
Cover page
IPO and concurrent private placement
WWB is conducting its initial public offering; there is no existing public market for its common shares. The shares have been approved for listing on the Nasdaq Global Select Market under ticker WWB, with delivery expected on or about November 16, 2026.
| Offering terms | Shares / amount |
|---|---|
| Common shares offered at $17.00 per share | 10.294117 million |
| Gross IPO proceeds | $175.0 million |
| Underwriting discounts and commissions | $12.25 million |
| Proceeds to WWB before offering expenses | $162.75 million |
| Underwriters’ 30-day option to purchase additional shares at the IPO price less discounts and commissions | Up to 1.544117 million |
Concurrently, Sanofi has agreed to purchase 1.532691 million common shares and pre-funded warrants for 1.408485 million additional shares for $50.0 million in total, at the $17.00 IPO price. The warrants have no exercise price. The private placement is expected to close alongside the IPO and is conditioned on the IPO closing; the IPO is not contingent on the placement. Underwriters acting as placement agents will receive a fee equal to 3.0% of the placement purchase price. The placement securities and warrant shares are unregistered and being issued under an exemption from registration.
Company and disclosure status
WWB is incorporated in Switzerland and qualifies as both a foreign private issuer and an emerging growth company. It may therefore use reduced U.S. public-company disclosure requirements. As a foreign private issuer, it is not required to file periodic reports and financial statements as frequently or promptly as U.S. domestic registrants. The prospectus describes the investment as carrying a high degree of risk and directs investors to its Risk Factors section.
About this prospectus
Windward Bio, the Company, and similar terms refer to Windward Bio Group AG and its consolidated subsidiaries. The section also includes a standard disclaimer regarding trademarks and trade names.
Presentation of financial information
Basis of presentation
WWB’s audited consolidated financial statements are prepared in accordance with IFRS as issued by the IASB, rather than U.S. GAAP. They cover December 31, 2025 and 2024, fiscal year 2025, and the inception period from July 5, 2024 through December 31, 2024. The unaudited condensed interim financial statements are prepared under IAS 34 and cover June 30, 2026 and the six months ended June 30, 2026 and 2025.
Currency translation and rounding
Prospectus amounts are in U.S. dollars unless otherwise stated. CHF amounts are generally translated at CHF 1.00 = $1.2372, the June 30, 2026 Federal Reserve Bank of New York noon buying rate. The preliminary, unaudited estimate of cash, cash equivalents and marketable securities as of September 30, 2026 uses CHF 1.00 = $1.1979, the September 30, 2026 rate. These translations are for convenience only and do not represent actual or potential convertibility at those rates. Some table totals may not equal the sum of displayed figures because of rounding.
Market industry and other data
WWB estimates that diseases targeted by its product candidates represent a $60 billion opportunity for biologic therapies and addressable patient populations. This is management’s estimate, based in part on its analysis of third-party information; WWB’s internal research and market definitions have not been independently verified. Industry and market estimates rely on projections and other inherently uncertain sources, and actual outcomes may differ materially because of risks affecting the company and its industry.
Prospectus summary
Company and opportunity
Windward Bio (WWB) is a clinical-stage biotechnology company incorporated in July 2024, with operations beginning in January 2025. It is developing ultra-long-acting antibodies for asthma, COPD and atopic dermatitis. The company estimates a combined $60B peak biologics-market opportunity across the diseases, with more than 100M people affected in the U.S., EU5 and Japan and over 8M potentially eligible for biologics. Estimated biologic-treatment penetration is about 20% in severe asthma, 1% in moderate-to-severe COPD and 15% in moderate-to-severe atopic dermatitis. WWB estimates 2025 global severe-asthma biologic sales at approximately $14B; asthma and COPD biologics together could reach $30B at peak. Biologics and novel oral treatments for atopic dermatitis generated an estimated $15B in 2025 and are projected to reach $30B at peak.
Pipeline and development
- WIN378 (anti-TSLP): Lead program, in Phase 2/3 development for severe asthma and Phase 2 development for COPD. In the 147-patient Phase 2 portion of POLARIS-1 (target enrollment 120), the reported half-life was up to 75 days. After one dose, effects through week 24 included FEV1 increases of up to 174 mL and placebo-adjusted mean increases of up to 267 mL (p=0.033), alongside improvements in FeNO and blood eosinophils. WWB says the results support the potential for twice-yearly subcutaneous dosing; two twice-yearly dose levels were selected. No treatment-related serious adverse events, withdrawals or discontinuations had been observed to date; adverse events were balanced versus placebo, injection-site reactions were below 1%, and antidrug antibodies were 2.2%. POLARIS-1 Phase 3 began in September 2026; POLARIS-2 recruitment is planned for H1 2027. Week-24 Phase 2 primary results are expected H1 2027, SIRIUS COPD topline results H2 2027, and topline results from both asthma Phase 3 studies H1 2029.
- WIN027 (dual anti-TSLP/anti-IL-13): In Phase 1 testing in healthy volunteers. Interim reports cite half-lives of 62 days and, in blinded data as of November 2, 2026, 84 days; low immunogenicity and low injection-site-reaction rates were reported. Full pharmacokinetic and immunogenicity data are expected H1 2027. Global Phase 2b COPD and Phase 2 atopic-dermatitis studies are planned to begin recruiting in H1 2027. Qyuns began Phase 2 studies in atopic dermatitis and chronic rhinosinusitis with nasal polyps in China in September 2026, plans an asthma Phase 2 study by year-end 2026, and expects topline results during 2027–2028.
- An additional T2/non-T2 bispecific program is in lead optimization, with Phase 1 targeted within 18 months, subject to regulatory requirements. WWB designs candidates for extended half-life, potency/affinity and low immunogenicity, aiming for less frequent dosing; improved convenience, adherence and outcomes remain hypotheses, not demonstrated commercial benefits.
Early or interim results may change with further data collection and do not establish later-stage safety or efficacy. Development also depends on enrollment, successful replication, regulatory review and third-party trial support. WWB relies on licensed rights: WIN378 is licensed from Kelun and HBM, excluding Greater China and certain Asian markets; Qyuns conducts China studies for WIN027. License obligations include potential milestone, royalty and other payments.
Historical financial results
WWB reports under IFRS. Its substantial losses are primarily driven by R&D spending.
| $M, except per-share data | H1 2026 | H1 2025 | FY 2025 | Jul. 5–Dec. 31, 2024* |
|---|---|---|---|---|
| R&D expense | 30.133 | 13.325 | — | — |
| G&A expense | 14.539 | 9.951 | — | — |
| Operating loss | 44.672 | 23.276 | 51.829 | 1.188 |
| Financial income | 2.164 | 0.673 | — | — |
| Net loss | 42.636 | 22.750 | 48.323 | 1.188 |
| Total comprehensive loss | 42.640 | 23.216 | 49.447 | 1.188 |
| Basic and diluted loss per share | $7.92 | $6.04 | $11.16 | $0.18 |
| Weighted-average shares (M) | 5.3845 | 3.7637 | 4.3297 | — |
*The 2024 period covers only July 5, 2024 (inception) through December 31, 2024, so it is not directly comparable with FY 2025.
At June 30, 2026, cash, cash equivalents and marketable securities were $207.299M (marketable securities are measured at FVTPL); total assets were $290.736M, liabilities $25.012M and equity $265.724M. After the charter amendment, preferred-share conversion and Series B warrant settlement, pro forma cash and marketable securities remain $207.3M and equity is $267.3M, including a $1.6M reclassification of the derivative warrant liability to equity. The liability will be remeasured at fair value immediately before settlement, and changes could affect earnings and the amount reclassified.
Offering, funding and shares
WWB has raised $310.0M through equity financings. Management preliminarily estimated $181.8M of cash, cash equivalents and marketable securities at September 30, 2026; this estimate is unaudited and subject to closing procedures. On October 30, 2026, Series B investors waived commitments to fund a $55.0M second tranche, though they may participate in the IPO. The company expects to require additional capital; inadequate financing could delay, reduce or terminate programs.
The proposed IPO is 10.2941M common shares at an assumed $17.00 per share, with a 30-day underwriters’ option for 1.5441M additional shares. Sanofi has agreed to a concurrent $50.0M private placement at $17.00 per share: 1.5327M common shares plus pre-funded warrants for 1.4085M shares, with no exercise price. The placement is expected to close with, but is not a condition to, the IPO; placement agents receive a 3.0% fee. Estimated net proceeds from the IPO and placement are $203.8M, or $228.0M with full exercise of the underwriters’ option. The filing also reports $225.0M of IPO gross proceeds; that amount does not reconcile with 10.2941M shares at $17.00.
Planned uses, together with existing funds, are $217.5M–$227.5M for WIN378 asthma/COPD trials and related R&D; $80M–$85M for WIN027 COPD/atopic-dermatitis trials and related R&D; and $5M–$10M for bispecific programs through IND-enabling studies. The remainder is for working capital and general corporate purposes. Pro forma as adjusted, assuming no underwriters’ option exercise, cash and marketable securities rise to $411.1M and equity to $471.1M.
Fully diluted share count (M; no greenshoe exercise):
| Share category | Shares |
|---|---|
| Common shares outstanding after offering and placement, including IPO shares, Sanofi common shares, preferred conversion and Series B warrant settlement | 58.0387 |
| 2025 Plan options (weighted-average exercise price $0.02) | 1.5530 |
| 2025 Plan RSUs | 0.5131 |
| 2026 Plan awards | 6.3000 |
| Employee Share Purchase Plan | 0.6300 |
| IPO option awards | 2.3900 |
| Sanofi pre-funded warrants | 1.4085 |
| Total, as calculated in the filing summary | 70.8334 |
The 58.0387M base excludes the securities listed separately, including Sanofi’s pre-funded warrants; IPO option awards are stated assuming full exercise of those warrants. The underwriters’ option is also excluded. Separately, pro forma basic and diluted weighted-average shares after preferred conversion and Series B warrant settlement are 40.2138M for FY 2025 and 41.2686M for H1 2026, with pro forma loss per share of $1.20 and $1.03, respectively; these figures exclude shares sold in the offering and private placement.
Principal risks and reporting status
WWB has a limited operating history, significant historical losses and expected continuing losses. Clinical outcomes, safety, approval and timelines are uncertain; market estimates and eventual physician, patient and payer acceptance may not be realized. Other risks include third-party performance, intellectual-property protection, licensing obligations, hiring and retention, regulation and healthcare reform, privacy/security compliance, dilution or relinquishment of rights to secure funding, and volatile trading.
As an emerging growth company, WWB uses reduced disclosure, including two years of audited financial statements and delayed auditor attestation on internal controls. As a Swiss foreign private issuer, it may report less frequently and promptly and may follow home-country governance practices instead of certain Nasdaq rules, reducing information and shareholder protections.
Special note regarding forward looking statement
Forward-Looking Statements
The company’s forward-looking statements concern its clinical-stage candidates, WIN378 and WIN027, including whether clinical trials will demonstrate acceptable safety and efficacy; the timing, progress, and results of trials; regulatory submissions, approvals, and compliance; potential indications, patient populations, market size, and advantages over existing therapies; and eventual commercialization and market acceptance.
Execution depends in part on the company’s ability to fund operating expenses and capital needs using existing cash and proceeds from the proposed offering and concurrent private placement, obtain additional financing if needed, and satisfy potential milestone and royalty obligations. Other uncertainties include competition and industry developments; expanding or acquiring product candidates; manufacturing and marketing capabilities, including reliance on contractors; protection of intellectual property and potential infringement claims; estimates of expenses and revenue; regulatory changes across jurisdictions; managing growth; and recruiting and retaining key personnel.
The company cautions that actual results may differ materially from its forward-looking statements. It gives no assurance that its plans or objectives will be achieved, or achieved on any particular timeline, and generally undertakes no obligation to update forward-looking statements except as required by law.
Risk factors
Business and clinical-development risk
WWB is a clinical-stage biotechnology company with no approved products, product revenue, or commercial-scale manufacturing or commercialization experience. Its prospects depend primarily on two licensed candidates: WIN378, an ultra-long-acting anti-TSLP antibody in the POLARIS Phase 2/3 asthma program and SIRIUS Phase 2 COPD study, and WIN027, an earlier-stage bispecific in Phase 1, with Phase 2 studies planned in COPD and atopic dermatitis. The anticipated twice-yearly dosing and other proposed advantages are not established clinical or commercial benefits; initial POLARIS-1 Phase 3 asthma readouts are expected in H1 2029.
Clinical success and timelines are uncertain. Early, interim, and preliminary findings may change after further data collection, audit, and review, and may not predict later results. Trials may fail efficacy or safety endpoints, reveal adverse events, enroll slowly, or require additional studies. WIN378’s early tolerability and dosing observations, and WIN027’s blinded interim findings—including a 62-day half-life—are not proof of safety or efficacy in larger patient populations. Delays, inconclusive results, or regulatory requests could increase costs, postpone or prevent approval, and worsen financing needs. Regulators may reject or restrict foreign trial data, including data generated in China; U.S. initiatives such as Operation TrailBlazer and proposed limits on Chinese trial data add uncertainty.
WWB relies on data, development work, and rights from licensors Kelun and HBM for WIN378 and Qyuns for WIN027. It has limited control over partners’ studies, reporting, regulatory compliance, funding, and priorities. PRC-related policy, geopolitical, export-control, sanctions, or data-transfer restrictions could disrupt access to data, technology, materials, manufacturing, or support. Kelun and HBM retain PRC rights to WIN378; Qyuns is conducting PRC development of WIN027, and its performance and funding could affect WWB’s global program.
Funding, licensing, and manufacturing
WWB reported net losses of $48.3 million for FY2025 and $42.6 million for H1 2026; accumulated losses were $93.2 million at June 30, 2026. Cash, cash equivalents, and marketable securities totaled $207.3 million at that date. WWB expects substantial and rising losses and estimates that offering and concurrent private-placement proceeds plus existing resources will fund planned operations and capital expenditures into H1 2029, including ongoing WIN378 trials, planned WIN027 studies, and bispecific discovery work. That estimate depends on assumptions and may prove wrong. Further capital will be needed; unavailable or unfavorable financing could force delays, reductions, or termination of programs. Equity or convertible financing could dilute shareholders; debt could add payments and covenants. As a Swiss company, WWB says it may have less flexibility to raise capital quickly.
License obligations could consume funds or put product rights at risk. For WIN378, the Kelun-HBM agreement provides for up to $320 million in development milestones (excluding $10 million already paid in 2025 and July 2026), up to $600 million in sales milestones per product, and tiered royalties from low single digits to low double digits. Subject to conditions, WWB may pay up to $73.75 million of the remaining first seven development milestones in shares; this could dilute investors and is subject to a 20% fully diluted ownership cap for Kelun and HBM. For WIN027, the Qyuns agreement provides for up to $100 million in development milestones, up to $570 million in sales milestones, and mid- to high-single-digit tiered royalties. Failure to meet obligations could result in termination and loss of licensed rights.
WWB owns no manufacturing facilities and depends on contractors for clinical supply and future commercial production. WIN378 production is transferring from Kelun’s PRC facilities to U.S. contractors, with completion expected by end-2026; a U.S. transfer for WIN027 is planned but has not begun. Transfers may delay trials or fail to achieve comparable quality, yield, or consistency. Contractor capacity, cGMP compliance, supply availability, and commercial-scale production remain uncertain; replacing a supplier can require qualification, regulatory review, and additional testing or trials.
Approval, market, and intellectual-property risks
Even approval may be delayed, limited to narrower indications, or subject to restrictive labeling, post-market studies, and ongoing compliance requirements. WWB has no sales, marketing, or distribution capabilities and must build them or partner, either of which requires resources and may leave it dependent on third parties. Adoption would depend on clinical differentiation, physician and patient acceptance, competition, coverage, reimbursement, and pricing. Larger competitors may offer better-established, safer, more effective, or less costly treatments, or reach the market sooner. Payors may demand discounts, cost-effectiveness evidence, or restrict access; foreign markets may impose price controls, and EU prices are generally below U.S. prices. Evolving U.S. and EU drug-pricing, reimbursement, and health-technology-assessment policies add uncertainty.
WWB’s prospects also depend on patent and trade-secret protection, much of it licensed or controlled by third parties. Patents may not issue, may be narrowed or invalidated, may be designed around, or may expire with little commercial exclusivity remaining. Patent litigation, third-party claims, licensing disputes, or failure by licensors to maintain or enforce rights could delay or prevent development, increase costs, or eliminate rights to a candidate. Patent laws and proceedings, including challenges to broad antibody claims, add risk.
Data, compliance, and operating risks
WWB and its vendors handle sensitive health and clinical-trial information and face cybersecurity threats, including ransomware and supply-chain attacks. The company and some service providers have experienced attack attempts or security incidents; losses were not quantified. Breaches could disrupt trials, expose data or IP, trigger investigations, litigation, penalties, and remediation costs, or require costly recovery of trial data. Privacy requirements vary and change across jurisdictions. Maximum stated fines include €20 million or 4% of global annual turnover under EU GDPR, £17.5 million or 4% under UK GDPR, and, for serious violations, RMB 50 million or 5% of prior-year annual revenue under China’s PIPL. Cross-border transfer restrictions and U.S. rules concerning sensitive data and countries of concern could constrain vendors and collaborations. AI use may create additional data and compliance exposure.
Healthcare-law, anti-corruption, product-liability, environmental, and regulatory compliance failures by WWB or third parties could lead to fines, litigation, restrictions, or reputational damage. WWB has approximately $10.0 million of aggregate product-liability insurance, which may not be adequate as trials expand or products are commercialized; it does not maintain environmental-liability or toxic-tort insurance. Growth also requires recruiting specialized staff and strengthening systems, while public-company reporting and control requirements add costs. Control testing could identify material weaknesses or require financial-statement revisions.
Shareholder and tax risks
WWB is incorporated in Switzerland and expects to use foreign-private-issuer and emerging-growth-company reporting exemptions, resulting in less frequent or less extensive disclosure and governance protections than for U.S. domestic issuers. Swiss law may make U.S. judgments and shareholder claims harder to pursue. The board may issue shares equal to 50% of registered share capital and rights to acquire shares equal to 30% through conditional capital in specified circumstances without statutory subscription rights; voting rights are capped at 14%. Insiders, major holders, and affiliates are expected to hold approximately 45.4% of voting shares after the offering and private placement, assuming the stated transaction conditions. Resales could add supply: 47,744,631 shares (82%) are initially restricted, generally by a 180-day lock-up, while holders of approximately 33,970,216 shares (59%) have registration rights. The IPO price of $17.00 exceeded pro forma as-adjusted net tangible book value of $10.26 per share at June 30, 2026, implying $6.74 per-share immediate dilution to IPO purchasers. WWB does not expect to pay dividends.
At December 31, 2025, Swiss tax-loss carryforwards were $40.2 million; they expire after ten years, and WWB considers it highly likely that some or all may expire unused. Tax-authority challenges, changing tax rules, or unfavorable audits could increase taxes and reduce cash flows.
Use of proceeds
Use of proceeds
WWB expects approximately $155.6 million in net proceeds from selling 10.2941 million common shares at $17.00 per share. If underwriters fully exercise their option to buy an additional 1.5441 million shares, estimated offering proceeds would increase to $179.7 million. A concurrent private placement to Sanofi is expected to provide an additional $48.2 million net.
The offering is intended to establish a public market for WWB’s shares, increase visibility, facilitate future access to equity markets, and raise capital. WWB expects to use the offering and private-placement proceeds together with existing cash, cash equivalents, and marketable securities, principally to fund research and development:
| Planned use | Expected allocation |
|---|---|
| Complete the WIN378 POLARIS-1 Phase 2/3 and confirmatory POLARIS-2 Phase 3 asthma trials; continue the SIRIUS Phase 2 COPD trial; and support related development, regulatory, research, clinical-supply, and manufacturing activities | $217.5M–$227.5M |
| Planned global Phase 2b WIN027 COPD and Phase 2 WIN027 atopic dermatitis trials and related R&D | $80M–$85M |
| Advance bispecific programs through IND-enabling studies | $5M–$10M |
| Remaining proceeds | Working capital and general corporate purposes, including personnel, facilities, and other operating expenses |
The stated R&D allocations exceed the expected proceeds from the offering and Sanofi placement. WWB therefore expects it will need additional funds to fully accomplish its planned uses. Management estimates that existing resources plus transaction proceeds will fund operating expenses and capital expenditure requirements into the first half of 2029, but this estimate depends on assumptions that may prove incorrect. Spending could accelerate with clinical progress, patient enrollment, regulatory requirements, trial outcomes, partnerships, or other cash needs.
As of the prospectus date, WWB had no committed external funding sources. It may seek additional financing through equity or debt offerings, credit facilities, or other sources. Management may also use proceeds to license, acquire, or invest in product candidates or technologies, although no such agreements or commitments existed. Until funds are used, WWB intends to invest them in capital-preservation instruments, including investment-grade corporate bonds, fixed-income instruments, money-market funds, and interest-bearing deposits; investment returns are not guaranteed, and management retains broad discretion over the use of proceeds.
Dividend policy
WWB has never declared or paid dividends and expects continued losses for the foreseeable future. It does not currently anticipate paying dividends on its common shares; investors’ returns therefore depend on share-price appreciation rather than dividend income. Any future dividend decision is at the board’s discretion and would depend on financial results, capital requirements and condition, contractual restrictions, business prospects, debt agreements, and applicable law.
WWB is a holding company with no material direct operations and relies largely on distributions from its subsidiaries to fund any dividend to shareholders. Local laws may restrict subsidiary distributions, limiting the parent company’s ability to pay. Swiss law also imposes requirements: dividends generally must be proposed by the board and approved by shareholders at a general meeting, with auditor confirmation of compliance, and must be supported by distributable profits or reserves in the company’s Swiss statutory standalone accounts after required allocations. Carried-forward losses must be offset first. While statutory retained earnings and capital reserves together are below 20% of paid-in nominal share capital, at least 5% of annual net income must be allocated to statutory retained earnings. Distributions from capital-contribution reserves are subject to sufficient freely distributable equity and statutory reserve thresholds; distributions from issued share capital require a capital reduction. Most dividends and other distributions are subject to Swiss federal withholding tax, subject to specified exceptions. Dividends left unclaimed for five years revert to the company and are allocated to statutory retained earnings.
Capitalization
Capitalization as of June 30, 2026
| USD millions, except shares | Actual | Pro forma | Pro forma as adjusted |
|---|---|---|---|
| Cash and cash equivalents | $18.9 | $18.9 | $222.7 |
| Total equity | $265.7 | $267.3 | $471.1 |
| Total capitalization | $265.7 | $267.3 | $471.1 |
| Common shares issued (millions) | 10.361646 | 46.245740 | 58.072548 |
The capitalization table presents no debt. Pro forma adjustments include conversion of 35.619 million preferred shares into common shares, reclassifying $0.7 million from preferred to common share capital. Cashless settlement of 264,998 Series B Warrants is modeled to deliver 264,714 common shares and increase pro forma equity by $1.6 million through reclassification of the derivative warrant liability.
Offering and financing
The pro forma-as-adjusted figures assume an IPO of 10.294117 million common shares at an assumed $17.00 per share, together with a concurrent Sanofi placement of 1.532691 million common shares and pre-funded warrants for 1.408485 million shares, also at an assumed $17.00 per share. The transactions are expected to generate $225.0 million of combined gross proceeds and $203.8 million of estimated net proceeds after underwriting, placement-agent and other offering expenses. The net proceeds increase cash from $18.9 million to $222.7 million and equity and total capitalization from $267.3 million to $471.1 million; $0.2 million is recorded in share capital and $203.6 million in reserves. The estimate assumes no underwriter option exercise, and final capitalization will depend on the final offering terms.
Shares and potential dilution
The stated post-offering share basis includes 10.327846 million common shares, including 4.527355 million restricted shares subject to repurchase, the preferred-share conversion, and 264,714 shares from the Series B Warrant cashless exercise.
| Potential shares excluded from outstanding count (millions) | Shares |
|---|---|
| 2025 Plan options: 1.296368 million outstanding at June 30 plus 0.256672 million granted subsequently; weighted-average exercise price $0.02 | 1.553040 |
| 2025 Plan RSUs: 0.379748 million outstanding plus 0.133334 million granted subsequently | 0.513082 |
| 2026 Plan awards | 6.300 |
| ESPP | 0.630 |
| IPO Award shares | 2.390010 |
| Sanofi pre-funded warrants | 1.408485 |
| Listed potential award and warrant shares | 12.794617 |
The listed total excludes 33,800 treasury shares and additional shares to be issued so treasury shares equal 10% of registered share capital; the additional amount is unspecified. The 12.794617 million figure is not a filing-stated fully diluted share count.
The Series B Warrant liability will be remeasured at fair value through profit or loss immediately before settlement. Any change in fair value since June 30, 2026 will affect earnings, and the amount ultimately reclassified to equity may differ from the estimate. The financing materially increases cash and equity, while the outstanding awards and pre-funded warrants represent substantial potential dilution.
Dilution
Dilution and pro forma capitalization
As of June 30, 2026, historical net tangible book value (NTBV) was $185.4 million, or $17.95 per share. After conversion of preferred shares and settlement of Series B warrants, pro forma NTBV was $187.0 million, or $4.05 per share—a $13.90 per-share decrease from the historical amount.
The IPO offers 10.294117 million common shares at $17.00 per share. Sanofi’s concurrent private placement comprises 1.532691 million common shares and pre-funded warrants for 1.408485 million shares, also priced at $17.00 per underlying share.
| Pro forma scenario | Estimated net proceeds | As-adjusted NTBV per share | Increase per share for existing shareholders | Dilution per share to new investors |
|---|---|---|---|---|
| No underwriters’ option exercise | $203.8M | $6.74 | $2.69 | $10.26 |
| Full exercise of 1.544117M-share option | $228.0M | $6.97 | $2.92 | $10.03 |
In the full-option scenario, estimated underwriting discounts and commissions are $14.1 million, offering expenses are $7.4 million, and concurrent-placement expenses are $1.8 million. Actual dilution may differ with the final offering price and terms; the filing’s estimates are illustrative.
Post-offering shares and consideration (no option exercise)
| Holder group | Shares (millions) | Share of shares | Consideration | Share of consideration | Weighted-average price |
|---|---|---|---|---|---|
| Existing shareholders | 46.211940 | 79.6% | $310.180M | 58.0% | $6.71 |
| New investors | 11.826808 | 20.4% | $225.000M | 42.0% | $17.00 |
| Total | 58.038748 | 100.0% | $535.180M | 100.0% | $9.00 |
The new-investor share count excludes the 1.408485 million shares underlying unexercised pre-funded warrants, although their proceeds are included in consideration. With full exercise of the underwriters’ option, existing holders’ share of the total would fall to 77.6% and new investors’ share would rise to 22.4%.
The 58.038748 million post-offering share count reflects preferred-share conversion and cashless exercise of Series B warrants: 264,714 common shares delivered from 264,998 warrants. It includes 4.527355 million restricted shares subject to repurchase rights.
Potential additional dilution
The following securities and plans are excluded from the post-offering share count:
- 1.296368 million options outstanding at June 30, 2026, and 0.256672 million options granted subsequently; each group has a $0.02 weighted-average exercise price.
- 0.379748 million outstanding restricted stock units (RSUs) and 0.133334 million RSUs subsequently granted.
- 6.300 million shares available under the 2026 Plan and 0.630 million under the employee stock purchase plan (ESPP).
- 2.390010 million IPO Award shares, based on the stated assumptions.
- 1.408485 million shares underlying the private-placement pre-funded warrants.
The company holds 33,800 treasury shares and expects additional share issuance related to capital increases so that treasury shares equal 10% of registered share capital. The filing cautions that option exercises, future equity awards or other issuances, and convertible debt securities could cause further dilution.
Management's discussion and analysis
Business and pipeline
WWB is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for respiratory and dermatologic diseases. It estimates a combined $60B peak biologics market opportunity across asthma, COPD and atopic dermatitis; more than 100M people in the U.S., EU5 and Japan are affected, and more than 8M are estimated to be eligible for biologics. WWB has no product revenue and does not expect product-sales revenue for several years, if ever.
- WIN378 (anti-TSLP): In the POLARIS-1 Phase 2/3 severe uncontrolled asthma study; its preplanned Phase 2 analysis was completed in H2 2026. The SIRIUS Phase 2 COPD study began in June 2026. Start-up for the second Phase 3 asthma study, POLARIS-2, began in September 2026, with recruitment planned for H1 2027.
- WIN027 (anti-TSLP×IL-13 bispecific): In a Phase 1 healthy-volunteer study assessing safety and pharmacokinetics, with U.S., Australian and Chinese INDs open. Start-up began in September 2026 for global Phase 2 studies in COPD and atopic dermatitis, with recruitment planned for H1 2027; full Phase 1 results are expected in H1 2027.
- The company’s strategy is to engineer antibodies for extended duration—including enhanced target affinity, dual-target binding or effector-function silencing—to enable less frequent dosing.
Financial performance
WWB has no revenue. Its operating losses reflect the cost of building the company and advancing clinical programs; interim and FY2025 spending increases were driven principally by WIN378 trials and related manufacturing, hiring, professional services and equity compensation.
| Consolidated results | H1 2026 | H1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating loss | $44.672M | $23.276M |
| Net loss | $42.636M | $22.750M |
| R&D expense | $30.133M | $13.325M |
| G&A expense | $14.539M | $9.951M |
H1 operating loss widened 92% and net loss 87%. R&D expense rose 126%: service and materials increased to $22.198M from $9.518M, mainly reflecting the start of WIN378’s asthma and COPD trials and related manufacturing. Payroll was $4.876M versus $2.131M, share-based compensation $2.861M versus $1.667M, and depreciation $0.198M versus $0.009M. G&A rose 46%, primarily due to external professional services and higher share-based compensation. Its components were operating expenses of $5.175M versus $3.167M, payroll of $3.286M versus $2.381M, share-based compensation of $5.949M versus $4.350M, and depreciation of $0.129M versus $0.053M.
| FY2025 results | FY2025 | July 5–Dec. 31, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating loss | $51.829M | $1.188M |
| Net loss | $48.323M | $1.188M |
| R&D expense | $32.592M | $0.084M |
| G&A expense | $19.237M | $1.104M |
The FY2025 and 2024 periods are not directly comparable: 2024 covers only the period since inception, when operations were at an early organizational stage. FY2025 R&D included $23.501M of service and materials, $5.866M of payroll, $3.108M of share-based compensation and $0.117M of depreciation. G&A included $6.813M of operating expenses, $5.462M of payroll, $6.823M of share-based compensation and $0.139M of depreciation. Total FY2025 R&D and G&A share-based compensation was $9.931M. FY2025 also included $3.593M of financial income, $0.005M of financial expense, $0.034M of net foreign-exchange loss and $0.048M of income-tax expense.
Cash flow and funding
| Cash flows | H1 2026 | H1 2025 |
|---|---|---|
| Operating cash used | $25.886M | $9.707M |
| Investing cash used | $83.300M | $51.281M |
| Financing cash provided | $108.576M | $73.788M |
| Net change in cash | $(0.610)M | $12.800M |
Higher operating cash use primarily reflected the larger net loss, partly offset by $1.7M more interest received. Investing cash use included financial-asset purchases and WIN027 license payments; the increase reflected $56.5M more financial-asset purchases, partly offset by $19.2M more proceeds from financial assets and lower license-related intangible-asset payments. Financing inflows primarily reflected the $110.0M first Series B tranche, compared with $75.0M from the first Series A tranche in H1 2025.
In FY2025, operating cash used was $33.262M, investing cash used $144.178M, financing cash provided $196.968M, and cash increased $19.528M. Investing included $194.2M of financial-asset purchases and $25.0M of WIN378 license payments ($20.0M upfront and a $5.0M milestone). Financing was mainly the $200.0M Series A proceeds, partly offset by $2.2M of transaction costs and $0.8M of lease payments.
Through June 30, 2026, WWB had received $310.0M gross from preferred-share issuances. Cash, cash equivalents and marketable securities totaled $207.3M at that date. Management expects these resources, together with net proceeds from the offering and concurrent private placement, to fund operations and capital expenditure requirements into H1 2029; the board considers resources sufficient for at least 12 months. The company nevertheless expects continued losses and rising R&D needs and remains dependent on external financing, which may be unavailable or dilutive; insufficient funding could require it to pause or terminate R&D or cease operations.
Series A raised $200.0M in two tranches: $75.0M in January 2025 and $125.0M in July 2025. The first Series B tranche closed in May 2026, issuing 10.6327M preferred shares at $10.35 each for $110.0M. The planned second tranche was waived on October 30, 2026, so no further Series B preferred shares will be issued under that agreement. Certain investors also received warrants to buy common shares at CHF 0.015 per share.
Licensing, accounting and risks
The WIN378 license from Kelun/HBM grants global rights excluding specified Asian territories, including Greater China. Upfront consideration totaled $40.0M ($20.0M cash and $20.0M equity). Development milestones can reach $320.0M, excluding two $5.0M milestones already achieved and paid (the second was paid in July 2026); sales milestones can reach $600.0M, plus tiered royalties from low single digits to low double digits. The WIN027 license from Qyuns grants global rights excluding Greater China; its $30.0M upfront ($15.0M cash and $15.0M equity) was paid in Q1 2026. Potential development and sales milestones total up to $100.0M and $570.0M, respectively, plus tiered mid- to high-single-digit royalties.
R&D costs are expensed as incurred under IFRS, and WWB does not track R&D expense by candidate, limiting program-level cost visibility. External-service and clinical-development accruals rely on estimates of completion; no material estimate-to-actual differences had occurred by June 30, 2026. IPR&D assets are not amortized; no impairment was recognized at that date, but recoverability depends on assumptions including market share, pricing, patent life, development costs, probability of success and discount rates. WWB recognizes no deferred tax assets for tax losses because future taxable profits are not considered probable. Its financial statements are prepared under IFRS and are not reconciled to U.S. GAAP.
At an assumed IPO price of $17.00 per share, WWB expects to grant options for 2,390,010 common shares under its 2026 Plan; exercise price will be based on the offering closing price, and the options will vest. Final fair value and compensation expense depend on the final offering price and completion of the 2026 financial statements. Before the offering, common-share grant-date fair values used third-party valuations and option-pricing or hybrid methods that considered differing common- and preferred-share rights.
WWB has no outstanding borrowings and considers interest-rate risk limited. It holds cash in highly liquid fixed-income instruments and money market funds, reports no expected-credit-loss provisions, and considers credit risk minimal. It has no formal FX hedging program and generally manages EUR and CHF exposure by holding cash in those currencies. For FY2025, a 10% strengthening/(weakening) against USD would have affected results by a $0.1M loss/(gain) for EUR/USD and a $1.3M loss/$1.5M gain for CHF/USD.
Business
Business and strategy
Windward Bio (WWB) is a clinical-stage biotechnology company founded in 2024 and launched in January 2025. It is developing long-acting antibody therapies, initially for asthma, COPD and atopic dermatitis (AD), with the aim of combining validated inflammatory targets with infrequent dosing, potency and low immunogenicity. The company has no approved products or product revenue; it funded operations principally through private equity placements and reported $207.3 million of cash, cash equivalents and marketable securities at June 30, 2026. It reports raising $310.0 million through equity financings. On October 30, 2026, Series B investors waived their commitments to fund a $55.0 million second tranche.
WWB estimates its initial disease areas affect about 100 million people across the U.S., EU5 and Japan, including more than 8 million people eligible for biologics, and represent a potential $60 billion peak market for biologic therapies. Management sees low biologic use and burdensome dosing as opportunities, but adoption, market size and product differentiation remain uncertain.
Pipeline and clinical progress
WIN378 is a fully human anti-TSLP antibody engineered for potential twice-yearly dosing. In Phase 1, it had a half-life of at least 65 days, was tolerated up to the highest dose studied, and showed low immunogenicity. In the Phase 2 dose-finding portion of POLARIS-1 for severe uncontrolled asthma, 147 patients were enrolled, exceeding the initial 120-patient target. Interim results through week 24 showed dose-dependent lung-function and inflammation improvements after one dose: FEV1 increased by up to 174 mL, with a placebo-adjusted increase of up to 267 mL (p=0.033); FeNO fell by up to 24 ppb (43%; p=0.006); and blood eosinophils fell by up to 200 cells/µL (51%; p<0.0001). Effects were near maximal by week 2 and sustained through week 24; population PK indicated a half-life of up to 75 days. No treatment-related serious adverse events, withdrawals or discontinuations were reported at the interim cutoff; adverse events were balanced against placebo, injection-site reactions affected fewer than 1%, and ADAs were reported in 2.2% of participants without observed pharmacologic or clinical effects. These interim findings are not proof of reduced exacerbations or pivotal-trial success.
The Phase 3 portion of POLARIS-1, evaluating two twice-yearly dose levels, began in September 2026; week-24 primary results are expected in H1 2027, week-48 Phase 2 results in H2 2027 and Phase 3 topline results in H1 2029. POLARIS-2 recruitment is planned for H1 2027, with topline results expected in H1 2029. The Phase 2 SIRIUS proof-of-concept study in COPD began in June 2026; topline results are expected in H2 2027. WWB’s proposed adherence advantage is based in part on research showing only 45% of asthma-biologic patients remain on therapy after one year; clinical benefit from twice-yearly dosing remains to be demonstrated.
WIN027 is a bispecific antibody targeting TSLP and IL-13, intended for dosing every 12 weeks or less frequently. Blinded Phase 1 data as of November 2, 2026 showed an 84-day half-life, low immunogenicity and few injection-site reactions. Among 75 participants in the safety population, no serious adverse events, deaths, discontinuations or withdrawals had been reported; all treatment-emergent adverse events were Grade 2 or lower. Full PK and immunogenicity results are expected in H1 2027. Global Phase 2b COPD and Phase 2 AD studies are planned to start in H1 2027; the COPD trial has registrational-quality features, while AD topline results are expected in H2 2028. Partner Qyuns began Phase 2 AD and chronic rhinosinusitis with nasal polyps studies in China in September 2026 and plans an asthma Phase 2 by year-end 2026, with results expected during 2027–2028. A further TSLP/non-TSLP bispecific program is in earlier development, with Phase 1 potentially within 18 months, subject to regulatory requirements.
Market opportunity, partnerships and execution
WWB estimates 2025 global severe-asthma biologic sales at approximately $14 billion and a potential $30 billion peak market for asthma and COPD biologics combined. It estimates 2025 global sales of systemic treatments for moderate-to-severe AD at approximately $15 billion, also projecting a $30 billion peak market. The company estimates that biologics reach about 20% of eligible severe-asthma patients, less than 1% of eligible COPD patients, and about 15% of eligible moderate-to-severe AD patients. Tezspire’s reported 2025 global sales of approximately $1.9 billion validate commercial interest in anti-TSLP, but comparisons of therapies’ efficacy cited by WWB are generally from separate trials, not head-to-head studies.
WWB has ex-Asia rights to WIN378 under the Kelun-HBM agreement and to WIN027 under the Qyuns agreement; partners retain rights in specified Asian territories. For WIN378, WWB paid a $20.0 million upfront fee, issued equity valued at $20.0 million in FY2025 and paid $10.0 million in development milestones. It may owe up to $320.0 million in additional development milestones and $600.0 million in commercial milestones per product, plus tiered low-single-digit to low-double-digit royalties. For WIN027, it paid a $15.0 million upfront fee and granted equity valued at $15.0 million in Q1 2026; potential obligations include up to $100.0 million in development milestones, $570.0 million in commercial milestones and tiered mid-single-digit to high-single-digit royalties. These are contingent future obligations, not amounts already paid.
WWB has no manufacturing facilities and relies on third parties for development and supply. It expects to transfer manufacturing to U.S. contract manufacturers before pivotal trials; device presentations are planned to move toward prefilled syringes or autoinjectors. These arrangements create supply, quality and timing dependencies. As of August 26, 2026, its owned and licensed portfolio comprised seven patent families, with patent protection for key WIN378 and WIN027 components and methods extending, as expected, into 2040–2047; patent scope and enforceability are uncertain.
Principal risks and resources
Both lead candidates remain investigational, and early safety, PK, biomarker and lung-function findings may not predict later efficacy or approval. Development timelines, regulatory reviews, manufacturing readiness and partner-led studies may be delayed or unsuccessful. Competition includes established therapies and other long-acting or bispecific candidates. Commercial prospects also depend on coverage, reimbursement, pricing and adoption; U.S. and foreign pricing reforms, payer scrutiny, healthcare regulation and changing market-access requirements could constrain sales or increase costs. WWB also faces clinical-data privacy and cross-border transfer obligations, including in China and the EU.
At September 30, 2026, WWB had 38 employees, including 24 in R&D; 17 held Ph.D. or M.D. degrees. Its principal office is leased in Basel through June 30, 2028. Management reported no pending litigation it believed would materially adversely affect the company.
Management
Leadership, board and governance
CEO and board chair Luca Santarelli, CFO Claudia D’Augusta, CMO Omar Khwaja, COO Kevin Harris, and Chief Legal and Corporate Development Officer Scott Applebaum have served in their current roles since January 2025. The team’s experience includes drug development, financing, commercialization, regulatory affairs and corporate transactions, including prior roles at VectivBio and Therachon, both acquired by larger companies.
The board has five members; WWB identifies all directors other than Santarelli as independent under Nasdaq definitions. Sandip Kapadia joined in May 2026, brings more than 25 years of life-sciences finance experience, chairs the audit committee and is the SEC-defined audit committee financial expert. The audit committee also includes Iqbal Mufti and Otello Stampacchia; all three are financially literate and independent under Exchange Act Rule 10A-3. Its responsibilities include financial reporting, internal controls and risk management, auditors, related-party transactions, cybersecurity, data privacy and ESG reporting. The compensation committee oversees executive and director compensation, performance targets, equity awards, clawbacks, human-capital policies and compensation risks. The governance and nomination committee oversees board composition, succession planning and governance. No family relationships among officers and directors are reported.
As a foreign private issuer, WWB may rely on home-country practices instead of certain Nasdaq requirements. Potential exemptions include quarterly Form 10-Q and specified-event Form 8-K reporting, Section 16(b) short-swing-profit liability, shareholder approval for certain securities issuances, and some requirements relating to compensation committees, related-party transactions and independent nomination oversight. The company says this may mean shareholders receive fewer protections than at companies subject to the full Nasdaq requirements, while stating that it intends to comply with the Nasdaq rules applicable to foreign private issuers. Directors, executives and principal shareholders are subject to insider-trading and ownership-change reporting under Sections 16(a) and 13, but not Section 16(b).
Compensation and equity incentives
For FY2025, reported aggregate compensation for board members and executive officers was $11.3 million. The filing separately reports $3.8 million in fees, salaries and other short-term benefits, $0.3 million in post-employment benefits set aside, and $14.3 million in share-based payments granted, of which $7.2 million was recognized as expense. Some share-based payments were outside IFRS 2 and excluded from Note 10. Directors and executives subscribed for 5.7372 million founder shares, including 2.6850 million subject to service and performance vesting under IFRS 2, at a stated fair value of $4.53 per share.
The 2026 Equity Incentive Plan became effective on the prospectus date; no awards had been made under it before effectiveness, and no further awards will be granted under the 2025 Plan. Its initial reserve is 6.3 million common shares, supplemented by shares returning from specified outstanding awards and agreements. From January 1, 2027 through 2036, the reserve automatically increases each year by 5.0% of common shares and unexercised pre-funded warrants outstanding at the preceding December 31, unless the board sets a lower amount. The ISO issuance limit is 18.9 million shares. The plan permits options, SARs, restricted shares and RSUs, performance and other awards, and gives the administrator broad authority, including specified authority to reprice or cancel and replace options or SARs.
WWB expects to grant illustrative options for 2,390,010 common shares under the plan, based on a $17.00 IPO price, sale of 10,294,117 shares in the IPO, and a concurrent private placement of 1,532,691 shares plus pre-funded warrants for 1,408,485 shares, generating $50.0 million in gross proceeds. The estimate assumes full warrant exercise and no underwriter option exercise; actual awards depend on the final post-offering fully diluted share count and agreed target ownership percentages.
At September 30, 2026, the 2025 Plan had options for 1,406,370 shares and 513,082 RSUs outstanding, with 1,240,374 shares available for future awards. Options generally have a nominal-value exercise price. The proposed employee stock purchase plan initially reserves 630,000 shares and permits annual increases from January 1, 2027 through January 1, 2036 capped at the lesser of 1.0% of year-end shares outstanding or 1,260,000 shares. Purchase prices generally are at least the lower of 85% of fair market value at the offering start or purchase date; offerings can last up to 27 months, and annual purchases are limited to $25,000 measured at the offering start.
Performance-plan administrators may exclude items such as restructuring and other unusual costs, FX effects, IFRS changes, acquisitions and divestitures, share-based compensation, dilution from share issuances, and goodwill or intangible impairments when assessing performance. They may also assume divested businesses achieved target performance for the remainder of a period, giving the company substantial discretion over incentive outcomes.
Founder shares, change of control and protections
In January 2025, WWB entered into founder share repurchase agreements covering common shares issued at incorporation. The shares include unrestricted, performance, first-tranche and second-tranche shares. Performance shares fully vested when the second-tranche Series A financing milestone was achieved in June 2025; other vesting is determined under the agreements by the board. Unvested shares may be repurchased in specified circumstances, including termination of service. In August 2025, employees also received 620,542 restricted shares at CHF 0.015 per share, for an aggregate issue price of CHF 9,308, subject to reverse vesting and company repurchase rights.
In March 2026, WWB acquired all shares of Windward Bio 27 AG from its executive-officer founders, issuing them 2,266,312 common shares in aggregate, fully paid through contribution in kind. These shares are subject to reverse vesting and repurchase rights, including for cessation of service and, for a specified number of shares, failure of the second tranche of the Series B financing to close.
Under the 2025 and 2026 founder agreements, while Santarelli remains a director, unvested founder shares accelerate upon a change of control unless a “Qualified Board Majority,” including his affirmative vote or consent, decides otherwise. Founders may sell vested shares to an acquirer at the transaction price, subject to the shareholders’ agreement; the board may require a sale, and if founders do not elect to sell, the company or its affiliates may repurchase the shares at that price. The 2025 Plan similarly provides for full acceleration of unvested awards on a change of control while Santarelli remains a director, unless that qualified majority decides otherwise. In contrast, 2026 Plan awards do not automatically accelerate unless the award or another written agreement provides for it; the administrator may cancel awards in a corporate transaction for cash, other consideration or no payment, and need not treat participants uniformly.
Beginning with the first annual general meeting as a public company, expected in 2027, Swiss law requires shareholders to elect compensation committee members and approve aggregate board and executive committee compensation. A proposed non-employee director policy provides a $40,000 annual cash retainer (or $60,000–$65,000 for a lead director), additional committee retainers of $5,000–$10,000 for members and $10,000–$20,000 for chairs, and options for 44,230 shares on appointment and 22,115 shares annually. These amounts remain subject to shareholder approval of maximum aggregate board compensation.
Subject to Swiss-law limits, WWB may indemnify directors and management and advance defense costs to the extent permitted by law and not covered by insurance or third parties; intentional or grossly negligent breaches are excluded. It maintains, or intends to enter into, directors’ and officers’ insurance and indemnification agreements. The company notes that the SEC considers indemnification for Securities Act liabilities contrary to public policy and unenforceable.
Material u s federal income tax considerations f
U.S. Federal Income Tax Considerations
Passive foreign investment company (PFIC) risk
The company does not believe it was a PFIC for the taxable year ended December 31, 2025. PFIC status is determined annually, however, and remains uncertain. The company has historically generated limited gross income, a material portion of which was passive, and may hold substantial cash after the offering; either factor could increase the risk of PFIC status. A substantial decline in the company’s market capitalization could also raise that risk. The determination is fact-intensive and subject to interpretive uncertainty and possible IRS challenge. U.S. counsel gives no opinion on the company’s PFIC status or its expectations.
If the company is a PFIC while a U.S. investor holds its shares, distributions exceeding 125% of the applicable three-year average and gains on a disposition may be subject to the PFIC excess-distribution regime. Amounts may be allocated over the investor’s holding period, with amounts allocated to prior years taxed at high ordinary-income rates and subject to an interest charge. PFIC treatment may continue for a holder in later years even after the company ceases to qualify, unless applicable requirements are met and the holder makes a deemed-sale election. Such an election can trigger tax on gain without providing cash proceeds. U.S. investors may also be affected by lower-tier PFICs, including tax on certain distributions or gains they do not directly receive.
A mark-to-market election may be available if the shares remain listed on Nasdaq or another qualified exchange and are regularly traded on at least 15 days in each calendar quarter. The election generally includes annual unrealized appreciation in ordinary income; losses are limited by prior inclusions. It does not protect investors from PFIC treatment of subsidiaries. The company does not expect to provide the information needed for a qualified electing fund election, so investors should assume that option will not be available. U.S. holders of PFIC shares generally must file Form 8621; failure to do so may result in penalties and extend the statute of limitations.
Distributions and disposition of shares
The company currently does not expect to pay distributions. If it does, distributions generally are treated as dividends to the extent of earnings and profits. Any excess generally first reduces the holder’s tax basis, then is treated as capital gain. Because the company may not calculate earnings and profits under U.S. tax principles, holders should expect distributions to be reported as dividends.
Dividend treatment, foreign tax credits, and eligibility for reduced qualified-dividend rates depend on the holder’s circumstances and other conditions, including that the company is not a PFIC in the year of the dividend or the preceding year. The company believes it qualifies for benefits under the U.S.–Switzerland income tax treaty and expects its Nasdaq-listed shares to be readily tradable, but gives no assurance that these conditions will be satisfied.
Absent PFIC rules, a U.S. holder generally recognizes capital gain or loss on a taxable disposition equal to the difference between proceeds and adjusted tax basis. The gain or loss is generally U.S.-source. For non-corporate holders, long-term gains generally receive reduced rates if the shares were held for more than one year.
Reporting and withholding
Payments may be subject to information reporting and backup withholding. Certain holders may also have foreign-asset reporting obligations.
Swiss tax implications for our holders
Swiss tax implications for holders
Distributions and withholding tax
Cash and in-kind dividends and similar distributions on WWB common shares are generally subject to Swiss federal withholding tax of 35% of the gross distribution, which the company withholds and remits. Qualifying distributions funded through permitted capital reductions or recognized capital-contribution reserves are exempt. Eligible non-Swiss holders may claim a partial or full refund under an applicable tax treaty. Eligible U.S. treaty residents may generally recover withholding above the 15% treaty rate, subject to treaty-benefit, beneficial-ownership, shareholding and other conditions. Refund claims are due by December 31 of the third year after the year the dividend was payable. Swiss-resident private holders generally may recover or credit withholding if they properly report dividends; similar relief applies to qualifying commercial holders that report the distribution.
Stamp and securities turnover taxes
The company is subject to Swiss issuance stamp duty of 1% of the offering price, net of certain deductions, on common shares issued, including over-allotment shares. Secondary-market transactions in shares involving a Swiss or Liechtenstein bank or securities dealer may be subject to securities turnover tax of up to 0.15% of consideration, subject to exemptions. Buybacks for cancellation are exempt from turnover tax; buybacks without cancellation are subject to it.
Income, gains and wealth taxation by holder type
- Nonresident holders: Generally owe no Swiss federal, cantonal or communal income tax on dividends, qualifying capital-return distributions or gains from share sales, and no Swiss wealth or capital tax.
- Swiss-resident private holders: Must report dividends as taxable income; qualifying capital-return distributions are excluded. Share-sale gains are generally tax-exempt, but losses are not deductible. A buyback for cancellation may produce taxable income to the extent the purchase price exceeds share capital and qualifying capital-contribution reserves. A non-cancelled buyback may avoid that treatment if the shares are resold within the generally six-year statutory holding period and the company remains within the generally 10% own-shareholding threshold. Swiss-resident individuals are subject to cantonal and communal private wealth tax on taxable wealth, including the shares.
- Domestic commercial holders: Generally include dividends, qualifying capital-return distributions, and share-sale gains or losses in taxable income. Buybacks are generally taxable to the extent the price exceeds book value. Corporate taxpayers may qualify for dividend relief if shares held as part of a Swiss business have an aggregate market value of at least CHF 1 million. Commercial corporate holders may face cantonal and communal capital tax on capital allocated to Switzerland.
Information exchange and uncertainty
Swiss automatic exchange of information (AEOI) agreements provide for collection and exchange of information on relevant financial assets, including shares and related income held through Swiss paying-agent accounts, for residents of the EU and other treaty states. Under the current U.S.–Swiss FATCA framework, information on U.S. accounts is disclosed with account-holder consent or exchanged through administrative-assistance procedures. A new agreement signed June 27, 2024 will route information through the Swiss Federal Tax Administration; Swiss legislation is required, and implementation is currently expected no earlier than January 1, 2029.
The tax discussion reflects Swiss law and practice as of its stated date, which may change, including retroactively. Actual tax outcomes depend on each investor’s circumstances and applicable treaty conditions.
Underwriting
Underwriting and offering terms
WWB’s November 12, 2026 underwriting agreement provides for an IPO of 10.2941 million common shares at $17.00 per share. The underwriters’ obligations are several, not joint, and subject to closing conditions; if they purchase any shares, they must purchase all shares, subject to the agreement’s default provisions.
| Offering proceeds | Base offering | Full option exercise |
|---|---|---|
| Shares sold | 10.2941M | 11.8382M |
| Gross proceeds | $175.000M | $201.250M |
| Underwriting discounts and commissions | $12.250M | $14.0875M |
| Proceeds to WWB before expenses | $162.750M | $187.1625M |
The underwriting discount and commission is $1.19 per share, leaving WWB $15.81 per share before expenses. Underwriters have a 30-day option to purchase up to 1.5441 million additional shares at the IPO price less discounts and commissions; it may be exercised only to cover sales exceeding the base offering. WWB estimates approximately $7.2 million in additional offering expenses, excluding underwriting discounts and concurrent private-placement placement-agent fees, and agreed to reimburse up to $40,000 of certain underwriter expenses.
Shares are allocated to Jefferies (3.6544M), TD Securities (2.8309M), Piper Sandler (2.1618M) and UBS (1.6471M). A concurrent private placement is separate from the underwriting, closes concurrently only if the IPO closes and customary conditions are met, and is not a condition to the IPO. The underwriters act as its placement agents and receive 3.0% of the private placement’s total purchase price.
Trading, resale and conflicts
There was no prior public market. The IPO price was negotiated and may not reflect the post-offering trading price. Nasdaq has approved listing under ticker WWB. The underwriters currently intend to make a market but are not obligated to do so and may stop at any time; liquidity and the ability to sell at favorable prices are not assured.
WWB, its officers and directors, and substantially all existing holders are generally subject to a 180-day lock-up, subject to specified exceptions. Representatives of Jefferies, TD Securities and Piper Sandler may waive restrictions before expiry. Exceptions include certain estate or affiliate transfers, equity-award settlements, preferred-share conversions and transactions approved by the representatives.
Underwriters may conduct stabilization, short-sale, syndicate-covering, penalty-bid and passive-market-making activities. These discretionary activities may support or maintain the share price above otherwise prevailing levels and may be discontinued at any time.
Potential conflicts and price pressure are also disclosed. Underwriters and affiliates may provide services to WWB for fees, trade or invest in its securities, and hedge lending exposure using credit-default swaps or short positions, including positions in the offered shares. They may also publish independent research or recommend long or short positions. Such trading and short positions could adversely affect future trading prices.
Jurisdictional selling restrictions
Sales are generally limited by jurisdiction-specific rules to qualified, professional, institutional or otherwise exempt investors. In Australia, eligible exempt-investor status is required and resale offers are generally restricted for 12 months unless an exemption applies. In Canada, distribution is limited to Ontario, Quebec, Alberta and British Columbia, with resales subject to applicable restrictions; Canadian purchasers may also face difficulty serving process on or enforcing judgments against WWB and its directors, officers or experts outside Canada. Certain Singapore investment-holding corporations and trusts face a six-month transfer restriction, subject to exceptions.
Public offers in the EEA and UK are limited to specified exemptions, including offers to qualified investors and, subject to consent, offers to fewer than 150 persons. Hong Kong, Israel, Japan and Switzerland also impose restrictions on public offers or sales; Japan requires an applicable registration exemption, and Switzerland prohibits public offers and local exchange listing.
Legal matters
- Legal matters: Niederer Kraft Frey AG will pass upon the validity of the common shares offered and certain Swiss-law matters, including Swiss income tax, for WWB. Cooley LLP will pass upon certain U.S. federal-law matters for WWB. The underwriters are represented by Advestra AG on Swiss-law matters and Latham & Watkins LLP on U.S. federal-law matters.
Experts
Ernst & Young AG, an independent registered public accounting firm, audited Windward Bio Group AG’s consolidated financial statements as of December 31, 2025 and 2024, for FY2025, and for the period from July 5, 2024 to December 31, 2024. The financial statements are included in the prospectus in reliance on the auditor’s report. This section provides no financial metrics, business developments, or company-specific risks.
Service of process and enforcement of liabilitie
Service of Process and Enforcement of Liabilities
WWB is incorporated and domiciled in Switzerland, where most of its assets are located. Most of its directors and executive officers reside outside the United States, and much of their personal assets may also be outside the United States. As a result, investors may have difficulty serving process on WWB or these individuals in the United States, or enforcing U.S. court judgments against them. The company also cautions that its conduct may not be subject to U.S. federal securities-law civil-liability provisions.
The United States and Switzerland have no treaty providing for reciprocal recognition and enforcement of civil and commercial judgments, other than arbitration awards. It is uncertain whether a U.S. civil-liability judgment—particularly one based on U.S. securities laws—would be enforceable in Switzerland. Swiss courts may recognize a final, enforceable U.S. judgment without reconsidering its merits, but only if Swiss-law requirements are met. These include proper jurisdiction under Swiss law; a final, non-appealable judgment; compliant service of process or the defendant’s unconditional participation; respect for material Swiss procedural rights; no conflicting qualifying Swiss or third-country proceeding; and consistency with Swiss public policy. Swiss courts may also reduce U.S. damages to the amount that compensates actual loss. Claims brought in Switzerland based solely on U.S. securities laws may face Swiss public-policy limitations and the application of mandatory Swiss law.
Swiss civil procedure differs materially from U.S. procedure. It does not provide U.S.-style pretrial discovery; evidence production is available only through limited judicial procedures and conditions, with the court determining what evidence is required and how the burden of proof applies. These differences may make it more difficult for investors to pursue claims and obtain evidence. WWB’s U.S. agent for service of process is Windward Bio, Inc.
Expenses of the offering
Expected offering expenses
Estimated offering expenses total $7,176,702, excluding underwriting discounts and commissions. Legal fees and expenses are the largest item. All amounts are estimates except the SEC registration, Nasdaq listing, and FINRA filing fees.
| Expense | Amount |
|---|---|
| SEC registration fee | $22,239 |
| Nasdaq listing fee | $325,000 |
| FINRA filing fee | $32,463 |
| Printing | $600,000 |
| Legal fees and expenses | $3,590,000 |
| Accounting fees and expenses | $950,000 |
| Miscellaneous costs | $1,657,000 |
| Total | $7,176,702 |
Where you can find additional information
Upon completion of the offering, WWB will report to the SEC as a foreign private issuer, filing annual reports on Form 20-F and reports on Form 6-K. Compared with U.S. domestic reporting companies, WWB is not required to file periodic reports and financial statements as frequently or promptly. It is also exempt from Exchange Act proxy-statement requirements, Section 16 provisions for recovery of short-swing profits by officers, directors and principal shareholders, and Regulation FD. These exemptions may result in investors receiving less information, or receiving it later, than investors in U.S. domestic issuers. SEC anti-fraud and anti-manipulation rules, including Rule 10b-5, continue to apply.
The prospectus does not include all information contained in the Form F-1 registration statement or its exhibits and schedules. WWB’s website is not incorporated into the prospectus.
Financial statements
Windward Bio Group AG — FY2025 financial statements
Windward Bio is a clinical-stage biotechnology company developing immunology treatments. It generated no product revenue in FY2025 and remains loss-making, with results and the 2024 comparison covering different periods: FY2025 is a full year, while the comparative period runs from incorporation on July 5 through December 31, 2024.
Results
| $ millions, except per-share data | FY2025 | July 5–Dec. 31, 2024 |
|---|---|---|
| Product revenue | $0 | $0 |
| Research and development expense | $32.592 | $0.084 |
| General and administrative expense | $19.237 | $1.104 |
| Operating loss | $(51.829) | $(1.188) |
| Financial income | $3.593 | — |
| Net loss | $(48.323) | $(1.188) |
| Basic and diluted loss per share | $(11.16) | $(0.18) |
Financial income included a $3.392 million realized and unrealized fair-value gain on financial assets at FVTPL and $0.201 million interest income. Financial expense was $0.005 million, net foreign-exchange loss was $0.034 million, and tax expense was $0.048 million. Total comprehensive loss was $49.447 million, including a $1.124 million pension remeasurement loss.
R&D expense primarily reflected $23.501 million of service and material costs, including third-party clinical development and manufacturing services, and $5.866 million of payroll. G&A included $6.813 million of operating costs, mainly legal, accounting and advisory services, and $5.462 million of payroll. Share-based compensation totaled $9.931 million—$3.108 million in R&D and $6.823 million in G&A—versus none in the comparative period.
Cash flow and financial position
| $ millions | FY2025 | July 5–Dec. 31, 2024 |
|---|---|---|
| Net cash used in operating activities | $(33.262) | $(0.074) |
| Capital expenditures (PP&E purchases) | $0.523 | — |
| Net cash used in investing activities | $(144.178) | — |
| Net cash from financing activities | $196.968 | — |
| Cash and cash equivalents, period end | $19.758 | $0.147 |
Investing outflows included $194.228 million of financial-asset purchases, partly offset by $75.736 million of proceeds from financial assets, and $25.000 million for intangible assets. Financing inflows were primarily $200.025 million of share issuance proceeds, net of $2.220 million issuance costs and $0.836 million of lease principal payments.
| $ millions, at Dec. 31 | 2025 | 2024 |
|---|---|---|
| Total assets | $219.297 | $0.183 |
| Total equity | $192.335 | $(1.077) |
| Total liabilities | $26.962 | $1.260 |
| Goodwill | $0 | $0 |
| Intangible assets other than goodwill | $75.000 | — |
| Cash and cash equivalents | $19.758 | $0.147 |
The intangible assets are acquired in-process R&D (IPR&D); no amortization or impairment was recorded. Financial assets totaled $140.196 million at year-end: $120.261 million at FVTPL ($87.537 million current and $32.724 million non-current) and $19.935 million at amortized cost. Financial liabilities were $25.735 million, including $15.000 million payable to Qyuns, $3.234 million of trade payables, $7.195 million of accrued expenses and other current liabilities, and $0.306 million of lease liabilities.
Funding, capital and development programs
The two 2025 Series A financing tranches generated approximately $200 million in cash. Common shares outstanding, net of treasury shares, increased from 6,666,710 at December 31, 2024 to 8,031,538 at December 31, 2025. At year-end, issued share capital comprised 8,095,334 common shares, 21,265,292 Series A Preferred Shares and 2,126,532 Series A Junior Preferred Shares; the difference between issued and outstanding common shares reflects 63,796 treasury shares. Both preferred classes mandatorily convert 1:1 into common shares upon an IPO. Series A has an 8% annual preferred dividend right if dividends are declared and liquidation priority over Series A Junior and common shares; Series A Junior ranks ahead of common.
FY2025 share-based compensation included $8.4 million recognized for founder shares. The company also granted 620,542 restricted shares at a weighted-average grant-date fair value of $4.88 and 84,934 options; 9,567 options were vested and exercisable at year-end. A further 2,971,710 granted common shares were unvested at year-end and excluded from EPS as anti-dilutive. Weighted-average shares used for EPS were 4.329678 million in FY2025 and 6.666710 million in the 2024 comparative period; share data and EPS were retrospectively adjusted for the reverse split.
The lead program, WIN378, is a long-acting anti-TSLP antibody. Its license involved $40.0 million of upfront consideration and a $5.0 million development milestone paid and capitalized in September 2025. Potential further payments include up to $330.0 million in development milestones and $600.0 million in sales milestones, plus tiered royalties. The Qyuns license for WIN027, a long-acting anti-TSLPxIL-13 bispecific program, provides for $30.0 million of upfront consideration, split between cash and equity; at year-end, $15.0 million was recorded as a cash payable and $15.0 million as an equity interest. It also carries up to $100.0 million in development and $570.0 million in sales milestones, plus royalties. Together, the licenses have up to $1.6 billion of stated development and sales milestones, before royalties. The acquired IPR&D is not amortized until available for use following relevant-market regulatory approval and is subject to impairment testing; the WIN378 valuation relies on uncertain Level 3 assumptions, including a 13.5% discount rate.
Windward Bio began consolidating LE2025 in December 2025, despite not yet holding its voting rights, because it committed nearly all of LE2025’s financing and guaranteed its obligations. It made available a revolving loan facility of up to $30.0 million. On March 4, 2026, LE2025 shareholders contributed their shares for 2,266,312 newly issued Windward Bio common shares, and LE2025 became wholly owned.
Liquidity, risks and subsequent events
At year-end, cash, cash equivalents and marketable securities totaled approximately $140.0 million. The board believed available resources could fund operations, recurring expenses and required capital expenditures for at least 12 months, although management expected continued losses and significant cash outflows and may extend runway by prioritizing spending. Cash was primarily denominated in CHF; a 10% CHF strengthening against USD would have reduced FY2025 results by $1.3 million, while a 10% weakening would have increased them by $1.5 million. Management considered credit and interest-rate risks limited and recorded no expected credit-loss provision.
The company has a limited operating history and depends on successful clinical development, regulatory approval, third parties and future financing; failure or abandonment of a program could require an IPR&D write-off. R&D costs are expensed as incurred, and CRO/CDMO accruals depend on estimates of service completion. The auditor issued an unmodified opinion; internal-control effectiveness was not audited.
Subsequent events included a $165.0 million Series B financing announcement: $110.0 million closed in May 2026, while the planned second tranche was waived in October, leaving the financing incomplete. In June 2026, a second WIN378 development milestone triggered a $5.0 million payment. In November 2026, Sanofi agreed to purchase common shares and pre-funded warrants for $50.0 million in a private placement expected to close with the IPO.
Financial statements
Windward Bio — H1 2026 financial statements
Windward Bio is a clinical-stage biotech with no product revenue to date. H1 spending increased as development activity expanded, widening the loss. The company’s first Series B tranche strengthened liquidity, while management expects continued losses and significant cash outflows and may seek additional capital.
Consolidated results
| USD millions, except per-share data | H1 2026 | H1 2025 |
|---|---|---|
| Product revenue | $0 | $0 |
| R&D expense | $30.133 | $13.325 |
| G&A expense | $14.539 | $9.951 |
| Operating loss | $(44.672) | $(23.276) |
| Financial income | $2.164 | $0.673 |
| Financial expense | $0.007 | $0.002 |
| Net loss | $(42.636) | $(22.750) |
| Total comprehensive loss | $(42.640) | $(23.216) |
| Basic and diluted loss per share | $(7.92) | $(6.04) |
| Weighted-average shares (millions) | 5.384501 | 3.763708 |
R&D rose 126.1%, driven mainly by clinical-development and manufacturing services and materials ($22.198 million versus $9.518 million) and payroll ($4.876 million versus $2.131 million). G&A growth included operating expenses of $5.175 million versus $3.167 million and payroll of $3.286 million versus $2.381 million. Financial income primarily reflected fair-value gains on financial assets at fair value through profit or loss: $2.081 million versus $0.616 million. The estimated effective tax rate was 0% in both periods. Potential shares were excluded from diluted EPS as anti-dilutive.
Cash flow
| USD millions | H1 2026 | H1 2025 |
|---|---|---|
| Operating cash flow | $(25.886) | $(9.707) |
| PP&E capital expenditures | $0.121 | $0.108 |
| Investing cash flow | $(83.300) | $(51.281) |
| Financing cash flow | $108.576 | $73.788 |
Operating cash flow included share-based payment expense of $8.810 million versus $6.017 million. Investing activity included $131.495 million of financial-asset purchases, $63.360 million of proceeds from financial assets, and $15.044 million spent on intangible assets. Financing inflows principally reflected $110.044 million of share and warrant proceeds. Cash declined $0.610 million in H1 2026 to $18.913 million, compared with an increase of $12.800 million in H1 2025 to $12.918 million.
Balance sheet and liquidity
| USD millions | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $290.736 | $219.297 |
| Total liabilities | $25.012 | $26.962 |
| Total equity | $265.724 | $192.335 |
| Cash and cash equivalents | $18.913 | $19.758 |
| Financial assets | $207.473 | $140.196 |
| Intangible assets (IPR&D) | $80.000 | $75.000 |
| Goodwill | Not separately reported | Not separately reported |
Reported tangible equity—equity less reported goodwill and intangible assets—was $185.724 million at June 30, 2026. Financial assets comprised $188.386 million at fair value through profit or loss, principally marketable securities, and $19.087 million at amortized cost; at year-end, the corresponding amounts were $120.261 million and $19.935 million. Management reported $207.3 million of cash, cash equivalents and marketable securities, up from $140.0 million, and said this was expected to fund operations for at least the next 12 months. It may reprioritize spending to extend runway.
The IPR&D carrying value increased by $5.000 million after a WIN378 development milestone was achieved on June 9. No impairment indicators were identified at June 30; the licenses were not ready for use or approved for sale. The company paid a $15.0 million WIN027 payable in January and issued 1,594,898 Series A Junior Preferred Shares as partial license consideration in March. Further development or sales milestones and royalties may be payable under both licenses.
Financial liabilities totaled $23.747 million at June 30 versus $25.735 million at year-end, including a new $1.567 million derivative warrant liability. Trade payables were $8.611 million versus $3.234 million; $8.1 million of accrued expenses and other current liabilities was due within 12 months. The warrants are classified as liabilities because they do not meet fixed-for-fixed equity classification; valuation uses a Level 3 adjusted Black-Scholes model. Marketable-security fair values use Level 1 inputs. Management reported no significant credit risk and limited interest-rate exposure.
Financing, equity compensation and obligations
On May 12, the first tranche of a Series B financing raised $110.0 million through 10,632,658 Series B Preferred Shares at $10.35 per share, with warrants issued to certain investors. The financing was launched for up to $165.0 million in two tranches; on October 30, 2026, parties waived the second tranche, so a further 5.316316 million preferred shares will not be issued. Warrants issued to investors in the Series A and Series B rounds totaled 264,998 and had a $1.6 million fair value at June 30.
| Post-split shares | January 1, 2026 | June 30, 2026 |
|---|---|---|
| Common | 8,031,538 | 10,327,846 |
| Series A Junior Preferred | 2,126,532 | 3,721,430 |
| Series A Preferred | 21,265,292 | 21,265,292 |
| Series B Preferred | — | 10,632,658 |
| Treasury shares | 63,796 | 33,800 |
Preferred shares convert 1:1 into common upon an IPO. Series A and B rank ahead of common in liquidation; Series B carries a non-cumulative 8% dividend right if declared.
H1 share-based compensation expense was $8.810 million ($2.8 million R&D; $6.0 million G&A). This included $5.7 million related to 2,266,312 founder shares issued subject to service conditions, valued at $5.93 per share. The company granted 379,748 RSUs at a $5.93 weighted-average grant-date fair value. Options outstanding rose to 1,296,368 from 84,934, including 1,211,434 grants; 103,114 were vested and exercisable. Options had a $0.02 weighted-average exercise price, $5.93 weighted-average grant-date fair value, 9.80-year remaining contractual life, and $2.0 million of H1 expense. At June 30, 4.527355 million granted but unvested common shares were excluded from EPS, versus 2.971710 million at year-end; options and other potential shares were also excluded where applicable.
A 3-for-2 reverse share split became effective November 6, 2026, and presented share and EPS information was retrospectively adjusted. The company also issued 5.100860 million common shares held in treasury, expected to be used in part for Series B warrant settlement. On November 9, Sanofi agreed to buy 1.532691 million common shares and pre-funded warrants for 1.408485 million common shares for $50 million in a private placement expected to close concurrently with the IPO.
The Swiss defined-benefit plan had a $1.265 million net liability at June 30 versus $1.227 million at year-end, based on a $17.220 million obligation and $15.955 million of plan assets. H1 pension expense was $0.233 million versus $0.158 million. Management expects continued losses and significant cash outflows; the company faces clinical, regulatory, financing, competition, intellectual-property and third-party-dependence risks.